Blacksmith Medicines Co-Founder Presents At The 21St International Conference On Biological Inorganic Chemistry
01 Aug 2025 17:10 GMT
(MENAFN- PR Newswire)
Presentation highlights Blacksmith's novel chemistry platform for targeting metalloenzymes and FG-2101, a first-in-class non-hydroxamate LpxC inhibitor
SAN DIEGO, Aug. 1, 2025 /PRNewswire/ -- Blacksmith Medicines, Inc. ( …
Yasir Al-Wakeel Appointed CEO of Vesalius Therapeutics and CEO-Partner of Flagship Pioneering
16 Sep 2025 11:45 GMT
… CEO of a stealth genetic medicines company. Previous roles include finance and …
Biomea Fusion Presents Data Demonstrating Enhanced Preclinical Activity of Icovamenib in Combination with Semaglutide in Type 2 Diabetes (T2D) Animal Model at the 61st EASD Annual MeetingĀ and Provides Additional Corporate Update
16 Sep 2025 11:00 GMT
… clinical-stage diabetes and obesity medicines company, today announced the presentation of … clinical-stage diabetes and obesity medicines company focused on the development of …
Biomea Fusion to Become a Diabetes & Obesity Medicines Company
13 Jan 2025 14:00 GMT
… become a diabetes and obesity medicines company. Based on the most recent …
Europe's 10 biggest healthtech deals in H1 2025
11 Sep 2025 10:48 GMT
… is a clinical-stage genetic medicines company based in Barcelona, pioneering Protein …